Obstacles and opportunities to improve antiretroviral regimen access in low-income countries.
Increasing evidence suggests that dramatically increasing access to effective and well-tolerated antiretroviral medications is key to reversing the HIV pandemic. Currently used first-line therapies in developing countries have multiple toxicities that cause significant morbidity and mortality. New World Health Organization HIV treatment guidelines support earlier treatment initiation and the use of less toxic first-line therapies. Adoption of these guidelines requires political and financial commitment from multiple stakeholders including country governments and donors. This review summarizes the major adverse effects associated with commonly used ARV regimens in low-income countries and also analyzes some of the barriers and potential solutions that affect the ability of low-income countries to implement the new World Health Organization guidelines.
Hospital of the University of Pennsylvania, 3400 Spruce Street, 3rd Floor Silverstein Building, Suite D, Philadelphia, PA 19104, USA. Jennifer.Cohn@uphs.upenn.edu
Jennifer
J
Cohn
Brook
B
Baker
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003906:Developing Countries; D004359:Drug Therapy, Combination; D019983:Guideline Adherence; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006297:Health Services Accessibility; D006801:Humans; D014944:World Health Organization
D019380:Anti-HIV Agents